The potential role of bisphosphonates in prostate cancer

Area of Science:

• Oncology
• Bone Biology
• Pharmacology

Background:

• Advanced prostate cancer frequently causes skeletal complications like bone metastases and osteoporosis.
• Osteoclast-mediated bone resorption contributes significantly to skeletal morbidity, even in sclerotic prostate cancer metastases.
• Bisphosphonates are established treatments for bone resorption but are now recognized for potential anti-tumor effects.

Purpose of the Study:

• To review the anti-tumor effects of bisphosphonates beyond their bone resorption inhibition.
• To assess preclinical and clinical evidence supporting bisphosphonates in managing prostate cancer bone metastases.

Main Methods:

• Literature review of preclinical studies on bisphosphonate anti-tumor activity.
• Analysis of clinical trial data evaluating bisphosphonates for prostate cancer bone metastases.
• Assessment of bisphosphonates' role in both treatment and prevention of bone metastases.

Main Results:

• Bisphosphonates demonstrate efficacy in inhibiting osteoclast-mediated bone resorption.
• Emerging evidence suggests bisphosphonates possess direct anti-tumor properties against prostate cancer cells.
• Both preclinical and clinical data support the use of bisphosphonates in managing bone metastases.

Conclusions:

• Bisphosphonates offer a dual benefit in advanced prostate cancer by reducing skeletal morbidity and potentially targeting tumor growth.
• Further investigation into the anti-tumor mechanisms of bisphosphonates is warranted.
• Bisphosphonates represent a valuable therapeutic option for patients with prostate cancer bone metastases.